About Qpex Biopharma
Qpex Biopharma is a company based in San Diego (United States) founded in 2018 was acquired by Shionogi in June 2023. Qpex Biopharma has raised $33 million across 1 funding round from investors including Shionogi, NEA and Adams Street Partners. The company has 12 employees as of December 31, 2022. Qpex Biopharma offers products and services including Antibiotics Development and Enzyme Inhibition Therapies. Qpex Biopharma operates in a competitive market with competitors including Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
- Headquarter San Diego, United States
- Employees 12 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Qpex Biopharma, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Qpex Biopharma
Qpex Biopharma offers a comprehensive portfolio of products and services, including Antibiotics Development and Enzyme Inhibition Therapies.
Creates new antibiotics to target drug-resistant pathogens effectively.
Develops therapies to inhibit enzymes and restore antibiotic potency.
People of Qpex Biopharma
Unlock access to complete
Leadership Team
4 people
Finance and Accounting
1 people
Operations Team
1 people
Product Management Team
1 people
Unlock access to complete
Funding Insights of Qpex Biopharma
Qpex Biopharma has successfully raised a total of $33M through 1 strategic funding round. The most recent funding activity was a Series A round of $33 million completed in July 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Qpex Biopharma
Qpex Biopharma has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Shionogi, NEA and Adams Street Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked | |
|
Private markets investment management with strategies in equity, credit, and secondary investments.
|
Locked | Locked | Locked | |
|
A global healthcare-focused VC/PE firm is operated.
|
Locked | Locked | Locked |
Investor details for Qpex Biopharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Qpex Biopharma
Investment portfolio details for Qpex Biopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Qpex Biopharma
Detailed financials for Qpex Biopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Qpex Biopharma Comparisons
Peer comparison for Qpex Biopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Qpex Biopharma
Qpex Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Spero Therapeutics, Nabriva, Melinta Therapeutics, Iterum Therapeutics and Adaptive Phage Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| Locked | Locked | Locked |
Pleuromutilin antibiotics are developed for MDR infections.
|
|
| Locked | Locked | Locked |
Developer of bacterial ribosome-targeting drugs for MDR infections
|
|
| Locked | Locked | Locked |
Developer of antibiotics for MDR infections
|
|
| Locked | Locked | Locked |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| Locked | Locked | Locked |
Therapeutics for antimicrobial resistant infections are developed.
|
Detailed competitors of Qpex Biopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Qpex Biopharma
Complete news archive for Qpex Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Qpex Biopharma
Qpex Biopharma was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Qpex Biopharma is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Michael Dudley is the current CEO of Qpex Biopharma.
Qpex Biopharma is a funded company, having raised a total of $33M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at Qpex Biopharma is 12.
Qpex Biopharma was founded in 2018 and is based in San Diego, United States. Operations focus on the biopharma sector, where therapies for infectious diseases are advanced. Proprietary beta-lactamase inhibitor technology is employed to develop antibiotics that address drug-resistant and gram-negative infections. Undisclosed anti-infective candidates are being progressed through this platform to tackle unmet needs in antimicrobial treatment.
Qpex Biopharma's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Qpex Biopharma offers Antibiotics Development and Enzyme Inhibition Therapies.
Qpex Biopharma has 5 investors. Key investors include Shionogi, NEA, Adams Street Partners, LYZZ Capital, and Hatteras Venture Partners.